{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:14:18Z","timestamp":1790493258490,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"crossref","award":["3-49679L"],"award-info":[{"award-number":["3-49679L"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.advms.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T02:03:42Z","timestamp":1415066622000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Upregulation of the sFas\/sFasL system in psoriatic patients"],"prefix":"10.1016","volume":"60","author":[{"given":"Hanna","family":"My\u015bliwiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"G\u00f3rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (4)","key":"10.1016\/j.advms.2014.10.005_bib0005","first-page":"373","article-title":"Psoriasis: cardiovascular risk factors and other disease comorbidities","volume":"7","author":"Wu","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.advms.2014.10.005_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000111512","article-title":"Association between psoriasis and the metabolic syndrome. A cross-sectional study","volume":"216","author":"Cohen","year":"2008","journal-title":"Dermatology"},{"issue":"December (12)","key":"10.1016\/j.advms.2014.10.005_bib0015","first-page":"1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"issue":"May (5)","key":"10.1016\/j.advms.2014.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.169.5.1747","article-title":"A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor","volume":"169","author":"Yonehara","year":"1989","journal-title":"J Exp Med"},{"issue":"February (3)","key":"10.1016\/j.advms.2014.10.005_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"issue":"May (10)","key":"10.1016\/j.advms.2014.10.005_bib0030","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.4049\/jimmunol.156.10.3638","article-title":"Regulation of the Fas lytic pathway in cloned CTL","volume":"156","author":"Glass","year":"1996","journal-title":"J Immunol"},{"issue":"May (9)","key":"10.1016\/j.advms.2014.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0006-2952(96)00732-0","article-title":"Antipsoriatic and proinflammatory action of anthralin Implications for the role of oxygen radicals","volume":"53","author":"Muller","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"February (2)","key":"10.1016\/j.advms.2014.10.005_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/1523-1747.ep12275369","article-title":"Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes","volume":"84","author":"Reichert","year":"1985","journal-title":"J Investig Dermatol"},{"issue":"April (4)","key":"10.1016\/j.advms.2014.10.005_bib0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/jphp.12019","article-title":"An investigation of the effects of dithranol-induced apoptosis in a human keratinocyte cell line","volume":"65","author":"George","year":"2013","journal-title":"J Pharm Pharmacol"},{"issue":"January\u2013February (1)","key":"10.1016\/j.advms.2014.10.005_bib0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000068289","article-title":"Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy","volume":"16","author":"Yamamoto","year":"2003","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"issue":"4","key":"10.1016\/j.advms.2014.10.005_bib0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"3","key":"10.1016\/j.advms.2014.10.005_bib0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The Psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"issue":"December (3)","key":"10.1016\/j.advms.2014.10.005_bib0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cyto.2010.09.012","article-title":"Effect of psoriasis activity on VEGF and its soluble receptor concentrations in serum and plaque scales","volume":"52","author":"Flisiak","year":"2010","journal-title":"Cytokine"},{"issue":"July (2)","key":"10.1016\/j.advms.2014.10.005_bib0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0092-8674(91)90614-5","article-title":"The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis","volume":"66","author":"Itoh","year":"1991","journal-title":"Cell"},{"issue":"May (5)","key":"10.1016\/j.advms.2014.10.005_bib0075","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.169.5.1747","article-title":"A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor","volume":"169","author":"Yonehara","year":"1989","journal-title":"J Exp Med"},{"issue":"December (6)","key":"10.1016\/j.advms.2014.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","article-title":"Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family","volume":"75","author":"Suda","year":"1993","journal-title":"Cell"},{"issue":"October (4)","key":"10.1016\/j.advms.2014.10.005_bib0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0168-8278(98)80145-1","article-title":"Serum levels of soluble Fas antigen in chronic hepatitis C patients","volume":"29","author":"Iio","year":"1998","journal-title":"J Hepatol"},{"issue":"January (1)","key":"10.1016\/j.advms.2014.10.005_bib0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/kei113","article-title":"Fas (CD95)-related apoptosis and rheumatoid arthritis","volume":"45","author":"Peng","year":"2006","journal-title":"Rheumatology"},{"issue":"September (1)","key":"10.1016\/j.advms.2014.10.005_bib0095","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1210\/jcem.86.9.7834","article-title":"Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease","volume":"86","author":"Feldkamp","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"February","key":"10.1016\/j.advms.2014.10.005_bib0100","article-title":"Pro-inflammatory adaptive cytokines and shed tumor necrosis factor receptors are elevated preceding systemic lupus erythematosus disease flare","author":"Munroe","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"August (8)","key":"10.1016\/j.advms.2014.10.005_bib0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1525-1594.2003.07274.x","article-title":"Soluble Fas: a novel marker of inflammation in uremia","volume":"27","author":"Dalboni","year":"2003","journal-title":"Artif Organs"},{"issue":"March (2)","key":"10.1016\/j.advms.2014.10.005_bib0110","first-page":"135","article-title":"Correlation between serum levels of soluble Fas (CD95\/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran","volume":"13","author":"Sahebari","year":"2010","journal-title":"Arch Iran Med"},{"issue":"July (1)","key":"10.1016\/j.advms.2014.10.005_bib0115","first-page":"5","article-title":"Fas and Fas ligand interactions in malignant disease","volume":"17","author":"Owen-Schaub","year":"2000","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.advms.2014.10.005_bib0120","first-page":"371","article-title":"Increased serum soluble Fas, tumor necrosis factor \u03b1 and interleukin 6 concentrations in generalized pustular psoriasis","volume":"196","author":"Seishima","year":"1998","journal-title":"Dermatology"},{"issue":"June (6)","key":"10.1016\/j.advms.2014.10.005_bib0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2362.2010.02293.x","article-title":"Relationship of sFas with metabolic risk factors and their clusters","volume":"40","author":"Tamakoshi","year":"2010","journal-title":"Eur J Clin Investig"},{"issue":"January (1)","key":"10.1016\/j.advms.2014.10.005_bib0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000250616.26308.d7","article-title":"Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST","volume":"27","author":"Blanco-Colio","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"May (5)","key":"10.1016\/j.advms.2014.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0272-6386(03)00202-6","article-title":"Soluble Fas: a novel predictor of atherosclerosis in dialysis patients","volume":"41","author":"Troyanov","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"April (7)","key":"10.1016\/j.advms.2014.10.005_bib0140","first-page":"789","article-title":"Prognostic value of apoptosis markers in advanced heart failure patients","volume":"30","author":"Niessner","year":"2009","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.advms.2014.10.005_bib0145","first-page":"297","article-title":"P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors","volume":"106","author":"Kolomecki","year":"2005","journal-title":"Bratisl Lek Listy"},{"issue":"April (8)","key":"10.1016\/j.advms.2014.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.187.8.1205","article-title":"Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity","volume":"187","author":"Schneider","year":"1998","journal-title":"J Exp Med"},{"issue":"February (1)","key":"10.1016\/j.advms.2014.10.005_bib0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08916930290005882","article-title":"Soluble Fas ligand-susceptible \u201cmemory\u201d cells in mice but not in human: potential role of soluble Fas ligand in deletion of auto-reactive cells","volume":"35","author":"Kim","year":"2002","journal-title":"Autoimmunity"},{"issue":"May (5)","key":"10.1016\/j.advms.2014.10.005_bib0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00004872-200205000-00024","article-title":"Soluble Fas ligand and atherosclerosis in hypertensive patients","volume":"20","author":"Okura","year":"2002","journal-title":"J Hypertens"},{"issue":"December (4)","key":"10.1016\/j.advms.2014.10.005_bib0165","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1365-2141.1998.01095.x","article-title":"Elevated serum soluble Fas ligand in natural killer cell proliferative disorders","volume":"103","author":"Kato","year":"1998","journal-title":"Br J Haematol"},{"issue":"July (2)","key":"10.1016\/j.advms.2014.10.005_bib0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4","article-title":"Significance of serum soluble Fas ligand in patients with bladder carcinoma","volume":"92","author":"Mizutani","year":"2001","journal-title":"Cancer"},{"issue":"July (7)","key":"10.1016\/j.advms.2014.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3748\/wjg.v9.i7.1415","article-title":"Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer","volume":"9","author":"Zheng","year":"2003","journal-title":"World J Gastroenterol"},{"issue":"March (3)","key":"10.1016\/j.advms.2014.10.005_bib0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-4632.2009.04258.x","article-title":"Genotoxic and apoptotic effects of Goeckerman therapy for psoriasis","volume":"49","author":"Borska","year":"2010","journal-title":"Int J Dermatol"},{"issue":"April (8)","key":"10.1016\/j.advms.2014.10.005_bib0185","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.189.8.1285","article-title":"A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation","volume":"189","author":"Hill","year":"1999","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.advms.2014.10.005_bib0190","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/ar2181","article-title":"Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis","volume":"9","author":"Kim","year":"2007","journal-title":"Arthritis Res Ther"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112614000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112614000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T16:32:43Z","timestamp":1689611563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112614000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1896112614000947"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2014.10.005","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upregulation of the sFas\/sFasL system in psoriatic patients","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}